Globally, there are approximately 58 million people with chronic hepatitis C virus infection (HCV) but only 20% have been diagnosed. HCV self-testing (HCVST) could reach those who have never been tested and increase uptake of HCV testing services.
A study, published in PLOS Global Public Health, compared cost per HCV viraemic diagnosis or cure for HCVST versus facility-based HCV testing services. The researchers used a decision analysis model with a one-year time horizon to examine the key drivers of economic cost per diagnosis or cure following the introduction of HCVST in China (men who have sex with men), Georgia (men 40–49 years), Viet Nam (people who inject drugs, PWID), and Kenya (PWID). HCV antibody prevalence ranged from 1%-60% across settings. Model parameters in each setting were informed by HCV testing and treatment programmes, HIV self-testing programmes, and expert opinion.
Full study results can be accessed here.